KHKi in HFI: Ketohexokinase Inhibition in Hereditary Fructose Intolerance
Study Details
Study Description
Brief Summary
Hereditary fructose intolerance (HFI) is a rare inborn error of metabolism. Patients with HFI develop acute abdominal pain, nausea, vomiting, hypoglycemia and proximal tubular dysfunction upon consumption of a fructose containing food product. In rare cases, (prolonged) fructose consumption can even lead to liver and kidney failure. Patients with HFI are therefore treated with a lifelong fructose-restricted diet. Animal studies have shown that the clinical manifestations of HFI are abrogated upon inhibition of ketohexokinase (KHK), the enzyme that catalyses the first step in fructose metabolism.
Recently, PF-06835919, a KHK inhibitor (KHKi), was developed as a new treatment for non-alcoholic fatty liver disease. The compound was well tolerated in several phase II clinical trials.
It is hypothesized that PF-06835919 is also effective in patients with HFI.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
Rationale: Hereditary fructose intolerance (HFI) is a rare inborn error of metabolism. Patients with HFI develop acute abdominal pain, nausea, vomiting, hypoglycemia and proximal tubular dysfunction upon consumption of a fructose containing food product. In rare cases, (prolonged) fructose consumption can even lead to liver and kidney failure. Patients with HFI are therefore treated with a lifelong fructose-restricted diet. Animal studies have shown that the clinical manifestations of HFI are abrogated upon inhibition of ketohexokinase (KHK), the enzyme that catalyses the first step in fructose metabolism.
Recently, PF-06835919, a KHK inhibitor (KHKi), was developed as a new treatment for non-alcoholic fatty liver disease. The compound was well tolerated in several phase II clinical trials.
It is hypothesized that PF-06835919 is also effective in patients with HFI. Objective: To study the effects of PF-06835919 on fructose tolerance and intrahepatic lipid content in patients with HFI. Study design: open-label, pilot study Study population: three adult patients with HFI will be treated with PF-06835919. Five adult healthy individuals will be included (but not be treated) as a reference. Intervention (if applicable): Patients receive once daily (in the morning) three tablets of 100 mg PF-06835919 for 9 days. They will subsequently be gradually exposed to increasing doses of either oral fructose or glucose (in a blinded fashion). Healthy individuals will only undergo oral fructose exposure, as a reference. Main study parameters/endpoints: Intrahepatic lipid content assessed by proton magnetic resonance spectroscopy (at baseline and completion), intestinal fructose tolerance (after oral fructose in comparison to oral glucose), hepatic fructose tolerance (serum glucose and phosphate after oral fructose in comparison to healthy individuals) and renal fructose tolerance (urinary glucose, phosphate, pH and amino acids after oral fructose in comparison to healthy individuals). Nature and extent
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: HFI patients HFI participants will receive PF-06835919 for 9 days. Dosage; once daily 300 mg PF-06835919 in the form of 3 tablets, oral. |
Drug: PF-06801591
Active ketohexokinase inhibitor
Other Names:
|
| No Intervention: Healthy controls Healthy controls will receive no intervention, but a single fructose tolerance test. |
Outcome Measures
Primary Outcome Measures
- Intestinal Fructose tolerance, [9 days]
a visual analog scale from 1-10 for abdominal pain will be used. Additional every 5 minutes the participant will be asked if he/she is nauseous, and more, less or similar nauseous as 5 minutes before.
- Intestinal Fructose tolerance, [9 days]
Every 5 minutes the participant will be asked if he/she is nauseous, and more, less or similar nauseous as 5 minutes before.
- Renal Fructose tolerance [9 days]
Urinary pH
- Renal Fructose tolerance [9 days]
Glucose content, mmol/L
- Renal Fructose tolerance [9 days]
Phosphate content mmol/L
- Renal Fructose tolerance [9 days]
Amino acid content mmol/L
- Hepatic fructose tolerance [9 days]
Serum glucose levels, mmol/L
- Hepatic fructose tolerance [9 days]
Serum phosphate levels, mmol/L
Secondary Outcome Measures
- Intrahepatic lipid content [9 days]
measured using 1H-MRS at baseline and completion
- Blood pressure [9 days]
measured at baseline and completion. Both systolic and diastolic pressure will be assessed
- Glycosylated transferrin [9 days]
measured at baseline and completion.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participants are able to provide signed and dated written informed consent prior to any study specific procedures
-
Use of effective contraception (only applicable to premenopausal women; a pregnancy test will be performed in these women at baseline)
-
Aged ≥ 18 years
Exclusion Criteria:
-
Diabetes mellitus
-
Pregnancy
-
Patients with congestive heart failure and/or severe renal and or liver insufficiency
-
Uncontrolled hypertension
-
Previous enrolment in a clinical study with an investigational product during the last 3 months or as judged by the investigator which would possibly hamper our study results
-
Use of drugs that inhibit organic anion transporting polypeptide B1 (OATPB1) transporters (e.g. rifampicin, gemfibrozil, ciclosporine, erythromcyin and clarithromycin)*
-
Treatment with irinotecan* Any contra-indications for MRI scanning*
-
Subjects who do not want to be informed about unexpected medical findings
-
Exclusion criterion for HFI patients only.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Maastricht University Medical centre | Maastricht | Limburg | Netherlands | 6202AZ |
Sponsors and Collaborators
- Maastricht University Medical Center
- Pfizer
Investigators
- Principal Investigator: Patrick Schrauwen, PhD, Maastricht University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NL83631.068.23 / METC23-006